GAETANO v. GILEAD SCIENCES, INC.

District Court, D. New Jersey·Decided July 27, 2021·No. 2:21-cv-01418·Unknown

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

ANTHONY GAETANO, Plaintiff, Civ. No. 21-01418 (KM) (JBC) v. OPINION GILEAD SCIENCES, INC., Defendant.

KEVIN MCNULTY, U.S.D.J.: This is a products liability action by a New Jersey resident, Anthony Gaetano, against Gilead Sciences, Inc., the maker of Truvada, an HIV prevention and treatment drug. Gilead moves pursuant to 28 U.S.C. § 1404(a) to transfer this case to its home district, the United States District Court for the Northern District of California (“Northern California”), where a number of similar actions are pending. (DE 23.)1 For the following reasons, the motion is DENIED. I. BACKGROUND A fuller background of the claims and issues is stated in my previous opinion in this case, Gaetano v. Gilead Sciences, Inc., --- F. Supp. 3d ----, Civ.

1 Certain citations to the record are abbreviated as follows: DE = docket entry Compl. = Complaint (DE 1-1) Reply = Gilead’s Reply Brief (DE 26) Anderson Decl. = Declaration of Joshua A. Anderson (DE 23-2) Gaetano Decl. = Declaration of Anthony Gaetano (DE 25) Answer = Gilead’s Answer to the Complaint (DE 17) Holley DE _ = docket entry in Holley v. Gilead Sciences, Inc., No. 18-cv-6972 (N.D. Cal.) No. 21-01418, 2021 WL 1153193 (D.N.J. Mar. 26, 2021) (“MTD”). To simplify the allegations, Truvada uses the active ingredient tenofovir disoproxil fumarate (“TDF”), which Gilead allegedly knew caused bone and kidney problems yet did not disclose. (Compl. ¶¶ 27, 33–36, 40–41.) Gilead also had discovered a similar active ingredient, tenofovir alafenamide fumarate (“TAF”), that did not pose the same risks as TDF. (Id. ¶¶ 58–60.) Yet Gilead discontinued its development of a TAF medication to instead focus on TDF medications. (Id. ¶¶ 61–63.) Mr. Gaetano took Truvada for nearly a decade and has experienced bone and kidney problems, which he alleges are related to Truvada. (Id. ¶ 8, 12, 18–19.) Mr. Gaetano sued Gilead in New Jersey Superior Court in July 2020, asserting claims under the New Jersey Product Liability Act (“NJPLA”), N.J. Stat. Ann. § 2A:58C-2, and for negligence. As to his NJPLA claim, he alleged two theories: (1) Truvada was defective because it caused kidney and bone damage, yet a safer alternative (TAF) was available; and (2) Truvada’s label failed to warn of risks. (Id. ¶¶ 72–80.) Gilead moved to dismiss, and the parties fully briefed that motion. When additional parties were dismissed, creating complete diversity, Gilead removed the case to this Court in January 2021, and its motion to dismiss was heard here. (DE 1, 4.) Gilead’s motion argued that all of Gaetano’s claims are preempted and that his failure-to-warn claim is precluded by New Jersey law. The preemption analysis required careful analysis attuned to the specific sub-theories asserted by Mr. Gaetano. See MTD, 2021 WL 1153193, at *2–11. My analysis relied particularly on an opinion by the Honorable Jon S. Tigar of the U.S. District Court for the Northern District of California, which largely denied an analogous motion to dismiss. See Holley v. Gilead Sciences, Inc., 379 F. Supp. 3d 809 (N.D. Cal. 2019). I agreed with Judge Tigar that most of the theories were not preempted. MTD, 2021 WL 1153193, at *5 n.5, *11 n.12.2 I thus denied Gilead’s motion to dismiss in its entirety. Gilead then answered, asserting

2 Judge Tigar did dismiss one sub-theory, which I did not. defenses that, among other things, implicate Mr. Gaetano’s physicians. (See, e.g., Answer ¶ 11 (comparative or contributory negligence), ¶ 30 (physicians did not rely on Gilead’s representations).) Even before I decided the motion to dismiss, the Holley litigation had grown to encompass many similar, consolidated actions by Truvada consumers against Gilead. (See Anderson Decl. ¶¶ 6–8.) As of the filing of the motion to transfer that is the subject of this Opinion, Holley encompassed thirty-three consolidated actions. (Id. ¶ 7.) In that mix are state-law claims by New Jersey plaintiffs. (Id.) Judge Tigar has coordinated the pre-trial phase for the consolidated cases. To that end, Judge Tigar adopted a schedule for bellwether trials. (Holley DE 709.) It appears that the parties are engaging in initial discovery for discovery pool cases. (Id.; Anderson Decl. ¶¶ 10–16.) Gilead has produced over 11.9 million pages of documents. (Anderson Decl. ¶ 11.) The plaintiffs have taken nineteen depositions of current or former Gilead employees and identified thirty-eight potential deponents. (Id. ¶¶ 12–15.) The first bellwether trial is set for January 2024. (Holley DE 709.) Citing this progress, Gilead moved to transfer this case to Northern California for consolidation with the Holley cases. Gilead additionally notes that it is headquartered in Northern California, and nearly all its witnesses and third-party witnesses (i.e., former Gilead employees or employees who may leave its employment in the near future) at least reside in the district. (Anderson Decl. ¶¶ 4–5.) Gaetano opposes transfer, citing, among other things, the facts that (1) he is an HIV-positive individual who suffers from diagnosed chronic pain that impacts his daily life and impedes travel; and (2) he is retired, and his income consists of $22,000 annually from social security and an extra $200 monthly from retirement savings. (Gaetano Decl. ¶¶ 2–5.) II. DISCUSSION A district court may transfer a case to another district pursuant to 28 U.S.C. 1404(a), which provides that “[f]or the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.” There is no dispute that this action could have been brought in Northern California.3 The decision to transfer, then, is left to the court’s discretion, guided by certain factors identified by the Third Circuit. In re: Howmedica Osteonics Corp, 867 F.3d 390, 401–02 (3d Cir. 2017). These factors require the Court to weigh private and public interests. I discuss each, plus case-specific considerations, and consider whether Gilead has carried its burden to show that they weigh in favor of transfer. Jumara v. State Farm Ins. Co., 55 F.3d 873, 879–80 (3d Cir. 1995). A. Private Interests The Third Circuit instructs that I consider the following private interests: • the plaintiff’s forum preference; • the defendant’s forum preference; • whether the claim arose elsewhere; • the convenience of the parties as indicated by their relative physical and financial condition; • the convenience of the witnesses, and the location of books and records; • all other practical problems that make trial of a case easy, expeditious, and inexpensive. Howmedica, 867 F.3d at 402. Starting with preferences, each party wishes to litigate in its home district. On this factor, a tie usually goes to the plaintiff, whose choice of forum “should not be lightly disturbed.” Jumara, 55 F.3d at 879 (citation omitted). It is true, as Gilead argues, that the plaintiff’s choice receives less weight “when the dispute at the heart of a lawsuit occurred almost entirely in another state.”

3 Gilead’s headquarters are within the Northern District of California. (Anderson Decl. ¶ 3.) The action thus could have been brought in that venue. See 28 U.S.C. § 1391

Free access — add to your briefcase to read the full text and ask questions with AI

GAETANO v. GILEAD SCIENCES, INC., (D.N.J. 2021).

GAETANO v. GILEAD SCIENCES, INC. (GAETANO v. GILEAD SCIENCES, INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Cohen v. Waxman
421 F. App'x 801 (Tenth Circuit, 2010)
Abraham v. St. Croix Renaissance Group, L.L.L.P.
719 F.3d 270 (Third Circuit, 2013)
Pharmacy Benefit Managers Antitrust Litigation
582 F.3d 432 (Third Circuit, 2009)
Yocham v. Novartis Pharmaceuticals Corp.
565 F. Supp. 2d 554 (D. New Jersey, 2008)
In Re Consolidated Parlodel Litigation
22 F. Supp. 2d 320 (D. New Jersey, 1998)
Sykes v. Glaxo-SmithKline
484 F. Supp. 2d 289 (E.D. Pennsylvania, 2007)
Clark v. Burger King Corp.
255 F. Supp. 2d 334 (D. New Jersey, 2003)
Tobias Chavez v. Dole Food Company Inc
836 F.3d 205 (Third Circuit, 2016)
In Re Howmedica Osteonics Corp.
867 F.3d 390 (Third Circuit, 2017)
Fernandes v. Deutsche Bank National Trust Co.
157 F. Supp. 3d 383 (D. New Jersey, 2015)
MaxLite, Inc. v. ATG Electronics, Inc.
193 F. Supp. 3d 371 (D. New Jersey, 2016)
Holley v. Gilead Scis., Inc.
379 F. Supp. 3d 809 (N.D. California, 2019)
Oien v. Thompson
824 F. Supp. 2d 898 (D. Minnesota, 2010)
Intellectual Ventures I LLC v. Altera Corp.
842 F. Supp. 2d 744 (D. Delaware, 2012)
McDonnell Douglas Corp. v. Polin
429 F.2d 30 (Third Circuit, 1970)